Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of SG12 in HBeAg-negative chronic hepatitis B patients on stable nucleos(t)ide analogue therapy
CTR20263987Phase 2Active
- Sponsor
- Sihegene
- Start
- Oct 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SG12 in Chronic Hepatitis B (CHB), sponsored by Sihegene. Started Oct 2026; status: active.
02
Drugs
SG12
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20263987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263987.